Problems Associated with Oligonucleotide Radiotherapy

TO THE EDITOR: We read with interest the article by Sedelnikova et al. (1). Their study was about a hot topic and was experimentally well designed. The authors found that 125I-oligodeoxynucleotides (ODNs) were more radiotoxic than 125I-antipyrine or 125I-bovine serum albumin; the former freely dissociates into cells, whereas the latter remains outside the cells. However, they found that the radiotoxicity of unbound 125I-ODN was significantly lower than that of DNA-incorporated 125I-deoxyuridine (UdR). Therefore, we would like to address a few issues for further discussion.

Lower toxicity often indicates lower usefulness in therapeutic applications, not the opposite. Thus, the results of Sedelnikova et al. may mean that ODN radiotherapy should be dropped from further development in similar experimental settings because enhanced cytotoxicity was not observed. We do not believe that this is the case. Importantly, nuclear localization alone when using Auger emitters does not ensure high radiotoxicity but rather high dose to nuclear DNA, as they showed (1).

It is possible to modify and increase the efficacy of radiotherapy delivered by ODNs by selecting optimal labels and carriers for each localization of particular targets (2,3). In this case, 125I-ODN was much weaker than 125I-UdR because of a lower concentration in the cell nucleus.

Furthermore, the liposomal delivery system may alter observed radiotoxicity considerably, and, in fact, it was not used with reference agents in the study of Sedelnikova et al.

Earlier (3), we used the term “oligoradionuclidetherapy” to describe more precisely the nature of therapy. The authors’ term, “gene radiotherapy,” could be used to describe all radiotherapeutic methods involving genes or any method using that sort of vehicle.

REFERENCES

Kalevi J.A. Kairemo
Antti P. Jekunen
Mikko Tenhunen
Helsinki University Central Hospital
Helsinki, Finland

REPLY: We thank Dr. Kairemo et al. for their interest in our research. The points they mention in their letter are the result of confusion of two newly developing radiotherapy approaches: gene radiotherapy proposed by us (1) and oligoradionuclidetherapy (ODN-RT) developed in their interesting publications (2,3). Both approaches use oligodeoxynucleotides (ODNs) for delivery of radioisotopes to the targets. The principal difference between gene radiotherapy and conventional radiotherapy (including ODN-RT) is that the former is aimed against specific genes or genomic rearrangements in the genome of the target cell(s), whereas the latter is based on delivery of a higher dose of radiation to the tumor, to the tumor cells and, consequently, to the total DNA of the tumor cells, since DNA is the main target of ionizing radiation.

Our concept of gene radiotherapy is based on sequence-specific delivery of radionucleides to the selected target(s) in the genome. Vehicles for this delivery could be triplex-forming ODNs, which are currently under investigation in our laboratory, or any other DNA-sequence-specific agents (peptides, proteins, polyamines and others). The principal goal of gene radiotherapy is to damage only the targeted gene or specific site in the genome while producing minimal damage to the rest of the genome. Therefore, only radioisotopes with a range of damage comparable with the diameter of the DNA molecule (approximately 2.0 nm) are useful for gene radiotherapy. The only class of radioisotopes that satisfy such a condition are Auger electron emitters.

The fact that our observed radiotoxicity for 125I-ODN is significantly lower than that of DNA-incorporated 125I-deoxyuridine (UdR) (1) means that the nuclear DNA was “out of reach” for very short-range Auger electrons generated by decay of 125I in the case of 125I-ODN. We predict no difference in radiotoxicity of 32P-ODN and DNA-incorporated 32P-deoxythymidine, for example. Therefore, addressing the first point, we do not believe that Kairemo et al. should give up ODN-RT. With the right choice of radioisotope, it is a quite promising approach, as they showed (2,3).

In regard to the point raised about the liposomal delivery system, we do not have data on radiotoxicity of the reference agents (125I-bovine serum albumin and 125I-antipyrine) delivered with liposomes. We agree that there is a possibility of redistribution of the above agents in cell culture in the presence of liposomes, although we do not believe that liposomes by themselves could affect dose dependence of cell survival curves.

REFERENCES

Igor G. Panyutin
Olga A. Sedelnikova
Ronald D. Neumann
National Institutes of Health
Bethesda, Maryland